Profile data is unavailable for this security.
About the company
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
- Revenue in INR (TTM)79.18bn
- Net income in INR4.33bn
- Incorporated1978
- Employees978.00
- LocationJubilant Pharmova Ltd1A, Sector 16ANOIDA 201301IndiaIND
- Phone+91 1 204361000
- Fax+91 1 204234881
- Websitehttps://www.jubl.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma Science Ltd | 47.26bn | 5.11bn | 76.77bn | 3.30k | 15.01 | -- | 10.54 | 1.62 | 55.49 | 55.49 | 512.73 | -- | -- | -- | -- | 14,315,680.00 | -- | -0.6014 | -- | -1.09 | 59.34 | 50.33 | 11.23 | -1.06 | -- | 8.50 | -- | -- | 17.36 | 10.65 | 437.22 | 52.50 | 10.08 | -22.16 |
| Marksans Pharma Ltd | 28.03bn | 3.60bn | 77.59bn | 1.35k | 21.51 | -- | 16.91 | 2.77 | 7.96 | 7.96 | 61.92 | -- | -- | -- | -- | 20,780,450.00 | -- | 14.15 | -- | 17.41 | 56.77 | 51.56 | 12.90 | 14.58 | -- | 20.42 | -- | 7.77 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Procter & Gamble Health Ltd | 13.49bn | 2.93bn | 80.66bn | 1.33k | 27.51 | -- | 25.50 | 5.98 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Viyash Scientific Ltd | 21.26bn | 768.08m | 87.69bn | 1.24k | 84.64 | -- | 43.56 | 4.13 | 2.37 | 2.37 | 70.40 | -- | -- | -- | -- | 17,086,170.00 | -- | 0.4014 | -- | 0.6553 | 51.15 | 42.16 | 4.52 | 0.4199 | -- | 3.92 | -- | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Sanofi India Ltd | 18.37bn | 3.27bn | 88.09bn | 991.00 | 26.96 | 11.76 | 24.20 | 4.79 | 141.85 | 141.85 | 797.77 | 325.31 | 1.28 | 2.20 | 9.04 | -- | 22.79 | 24.37 | 39.46 | 36.22 | 51.17 | 53.29 | 17.78 | 22.21 | 0.9951 | 267.06 | 0.0232 | 70.08 | -8.73 | -8.74 | 4.14 | -7.31 | -9.10 | -0.3221 |
| Corona Remedies Ltd | 13.44bn | 1.71bn | 94.51bn | 4.57k | 55.16 | -- | 45.23 | 7.03 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | 8.78bn | 2.40bn | 97.64bn | 583.00 | 40.67 | 25.43 | 38.78 | 11.12 | 104.25 | 104.25 | 381.40 | 166.73 | 1.80 | 4.48 | 40.57 | -- | 49.09 | -- | 66.76 | -- | 73.80 | -- | 27.33 | -- | 3.37 | 148.65 | 0.0607 | -- | 21.24 | -- | 32.65 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 111.80bn | 2.20k | 20.59 | -- | 18.18 | 4.45 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 114.06bn | 1.21k | 51.39 | -- | 33.21 | 5.56 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 125.46bn | 990.00 | 20.51 | -- | 18.10 | 6.00 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 125.67bn | 1.57k | 40.43 | -- | 33.01 | 10.85 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 132.13bn | 978.00 | 30.64 | -- | 15.58 | 1.67 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 137.26bn | 16.57k | 21.78 | -- | 14.84 | 1.89 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Granules India Ltd | 50.92bn | 5.45bn | 137.37bn | 4.07k | 24.66 | -- | 16.68 | 2.70 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 163.91bn | 1.80k | 91.51 | -- | 62.40 | 10.41 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 170.71bn | 4.20k | 10.96 | -- | 9.49 | 3.74 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
Data as of Mar 06 2026. Currency figures normalised to Jubilant Pharmova Ltd's reporting currency: Indian Rupee INR
19.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2025 | 5.00m | 3.14% |
| East Bridge Capital Management L.P.as of 31 Dec 2025 | 4.02m | 2.53% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Jan 2026 | 3.89m | 2.44% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 3.54m | 2.22% |
| quant Money Managers Ltd.as of 31 Dec 2025 | 2.95m | 1.85% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.76m | 1.74% |
| Th�l�me Partners LLPas of 31 Dec 2025 | 2.64m | 1.66% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.93m | 1.21% |
| Abakkus Asset Manager Pvt Ltd.as of 31 Dec 2025 | 1.84m | 1.15% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Jan 2026 | 1.73m | 1.09% |
More ▼
Data from 31 Dec 2024 - 15 Feb 2026Source: FactSet Research Systems Inc.
